Yongqian Shu

机构：Jiangsu Cancer Hospital, Jiangsu Province Hospital, Nanjing Medical University · ORCID：0000-0003-0802-1677

发表论文 84 篇 · 总被引 2770 次 · h-index 24

代表论文

• Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer (2023 · JAMA · 被引 383)
• First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial (2024 · The Lancet Respiratory Medicine · 被引 58)
• A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study (2024 · Cancer · 被引 17)
• Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 16)
• JP1 normalizes tumor vasculature to suppress metastasis and facilitate drug delivery by inhibiting IL-8 (2023 · JCI Insight · 被引 7)
• Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer (2025 · Translational Lung Cancer Research · 被引 2)